Trehalose Inhibits Human Immunodeficiency Virus Type 1 Infection in Primary Human Macrophages and CD4+ T Lymphocytes

Pratima Rawat1, Simson Hon1, Carmen Teodorof-Diedrich1

  • 1Department of Pediatrics, Division of Infectious Diseases, University of California San Diego, La Jolla, California, USA.

Journal of Virology
|June 20, 2020
PubMed

Insights

Trehalose, a natural sugar, inhibits HIV by boosting autophagy and reducing viral entry into cells. This dual action offers a novel therapeutic strategy against HIV infection in macrophages and T cells.

Area of Science:

  • Cellular Biology
  • Virology
  • Immunology

Background:

  • Autophagy is a cellular recycling process crucial for cell survival under stress.
  • Inhibiting mechanistic target of rapamycin (MTOR) induces autophagy and reduces HIV replication.
  • MTOR inhibition has broader effects beyond autophagy that can influence viral replication.

Purpose of the Study:

  • To investigate the effect of trehalose, an MTOR-independent autophagy inducer, on HIV replication.
  • To elucidate the mechanisms by which trehalose inhibits HIV in human macrophages and CD4+ T lymphocytes.

Main Methods:

  • Treatment of HIV-infected macrophages and T cells with trehalose.
  • Assessment of autophagy markers (LC3B lipidation, LAMP1, LAMP2, RAB7).
  • Evaluation of HIV entry by measuring CCR5 and CD4 expression.
  • Analysis of trehalose's effect upon ATG5 gene knockdown.

Main Results:

  • Trehalose inhibited HIV replication in a dose-dependent manner in macrophages and T cells.
  • Trehalose treatment increased autophagy markers and lysosomal biogenesis proteins.
  • HIV inhibition by trehalose was dependent on ATG5, confirming autophagy's role.
  • Trehalose reduced HIV entry by downregulating CCR5 and CD4 expression.

Conclusions:

  • Trehalose inhibits HIV through MTOR-independent autophagy-mediated degradation and by decreasing viral entry.
  • The downregulation of CCR5 and CD4 by trehalose represents a novel mechanism for inhibiting HIV entry.
  • Trehalose is a promising, naturally occurring compound for combating HIV infection via dual antiviral mechanisms.